Paul Tudor Jones Roivant Sciences Ltd. Transaction History

Tudor Investment Corp Et Al

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$10.36 - $11.74 $1.27 Million - $1.44 Million	-122,916 Reduced 70.84%	50,599 $534,000
Q1 2024 May 15, 2024	SELL	$9.87 - $11.8 $1.18 Million - $1.42 Million	-120,000 Reduced 40.88%	173,515 $1.83 Million
Q4 2023 Feb 14, 2024	BUY	$8.38 - $11.58 $953,551 - $1.32 Million	113,789 Added 63.31%	293,515 $3.3 Million
Q3 2023 Nov 15, 2023	SELL	$9.76 - $13.19 $1.47 Million - $1.99 Million	-150,865 Reduced 45.63%	179,726 $2.1 Million
Q2 2023 Aug 14, 2023	SELL	$7.09 - $10.08 $379,400 - $539,400	-53,512 Reduced 13.93%	330,591 $3.33 Million
Q1 2023 May 15, 2023	BUY	$6.92 - $9.98 $1.47 Million - $2.12 Million	212,355 Added 123.64%	384,103 $2.84 Million
Q4 2022 Feb 14, 2023	SELL	$3.36 - $7.99 $612,699 - $1.46 Million	-182,351 Reduced 51.5%	171,748 $1.37 Million
Q3 2022 Nov 14, 2022	BUY	$0.51 - $4.84 $149,664 - $1.42 Million	293,459 Added 483.94%	354,099 $1.14 Million
Q2 2022 Aug 15, 2022	BUY	$2.81 - $4.84 $170,398 - $293,497	60,640 New	60,640 $247,000

311

508M

1.26M

2.52M

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $8.95B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.